Business
Race Oncology (ASX:RAC) share price slides on a new melanoma preclinical study
The Race Oncology Ltd (ASX: RAC) share price is sliding today, despite the announcement of a new preclinical study by the specialty pharmaceutical company. At the time of writing, shares are down 0.5% to $3.98.
Race Oncology share price unfazed by Bisantrene study
Race Oncology focuses on the development of cancer-targeting drugs in an effort towards better outcomes. The company’s flagship drug is Bisantrene, a small molecule inhibitor of the fat mass and obesity-associated (FTO) protein. A link between FTO and a range of cancers has led Race to investigate Bisantrene further.
According to the release, Race has now entered…
-
General14 hours agoCoroner to examine treatment of woman who died three days after surgery performed by former Queensland premier’s partner
-
General15 hours agoToo skewed, too gentlemanly | The Spectator Australia
-
General17 hours agoAlbanese beats drum on economy as trade clouds gather
-
Noosa News16 hours agoSurgeon partner of former premier to testify over his patient’s death